| LY2584702p70 S6 kinaseinhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1]: | |
Cell lines | HCT116 colon cancer cells |
Preparation method | The solubility of this compound in DMSO is >22.3mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | N/A |
Applications | In HCT116 colon cancer cells, LY2584702 inhibited phosphorylation of the S6 ribosomal protein (pS6) with an IC50 of 0.1-0.24 uM. |
| Animal experiment [1]: | |
Animal models | U87MG glioblastoma and HCT116 colon carcinoma xenograft models |
Dosage form | 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID |
Application | In both U87MG glioblastoma and HCT116 colon carcinoma xenograft models, LY2584702 exhibited significant single-agent efficacy. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Tolcher A, Goldman J, Patnaik A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur J Cancer, 2014, 50(5): 867-875. | |
LY2584702 Dilution Calculator
calculate
LY2584702 Molarity Calculator
calculate
| Cas No. | 1082949-67-4 | SDF | Download SDF |
| Chemical Name | 4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)piperidin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine | ||
| Canonical SMILES | CN(C(C1CCN(C2=NC=NC3=NNC=C32)CC1)=N4)C=C4C5=CC(C(F)(F)F)=C(F)C=C5 | ||
| Formula | C21H19F4N7 | M.Wt | 445.42 |
| Solubility | ≥22.25mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
LY2584702 is a potent and selective inhibitor of p70 S6 kinase with IC50 value of 4 nM [1].
P70 S6 kinase (p70S6K) is a serine/threonine protein kinase that acts downstream of the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signalling pathway. p70S6K phosphorylates the eukaryotic initiation factor 4B (eIF4B), a regulator of protein synthesis, and phosphorylates and activates ribosomal protein S6 (S6), a component of the 40S ribosomal subunit [1] [2].
LY2584702 is an oral and selective ATP competitive p70S6K inhibitor. In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of S6 (pS6) with IC50 value of 0.1-0.24 μM [1].
In the HCT116 colon carcinoma xenograft model, LY2584702 significantly inhibited tumour growth with threshold minimum effective dose 50% (TMED50) and TMED90 of 2.3 mg/kg and 10 mg/kg, respectively. In both HCT116 colon carcinoma and U87MG glioblastoma xenograft models, LY2584702 at levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID exhibited significant efficacy. Treatment patients with advanced solid tumours with LY2584702 orally on a 28-day cycle, the maximum tolerated dose (MTD) was 75 mg BID (twice-daily) or 100 mg QD (once-daily) [1].
References:[1]. Tolcher A, Goldman J, Patnaik A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur J Cancer, 2014, 50(5): 867-875.[2]. Hollebecque A, Houédé N, Cohen EE, et al. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer, 2014, 50(5): 876-884.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
其次要看下你选择单位的规模如何，做的比较好的，还是上海这边的，你可以看下基尔顿生物，原代细胞培养，动物造模，整体课题外包。
不建议你用MDCK细胞，非常难转染。
GFP发出绿色荧光的原理是Ca离子进入GFP的beta-barrel结构中引起的特定能级，因此只要这个结构仍然保持着，就可以发出荧光。
由于GFP的beta-barrel结构非常稳定，一些版本的GFP蛋白（如EGFP）甚至能抵抗94C的高温几分钟而不完全变性，因此想在溶液状态下去掉GFP的荧光是很难的，一般需要用光漂白法。
基于其非常稳定的结构，即便细胞被固定了，仍然会有一部分的GFP蛋白保持其构象而发出荧光。此时荧光可能较弱。在荧光显微镜下是有可能看得到的。
我刚开始做转染，悬浮细胞，分别做过表达和敲减，看了很多文献，大都没有提及转染后是用转染的这同一批细胞同时做pcr，wb，cck8，凋亡，细胞周期；还是说这次转染只做pcr或wb，再转染一次做cck8或细胞周期。剩下的功能试验均同前，转染一次做一次？我养的是悬浮细胞，转染后做cck8这些功能试验前需要离心换液吗？跪谢解答！
可以用移液器将细胞吸出来并高速离心，沉淀重悬于PBS中洗涤，接着就可以裂解提取蛋白了。可以用超声，酶解等等，裂解后离心收集上清。
其次要看下你选择单位的规模如何，上海这边的，你可以看下基尔顿生物，原代细胞培养，动物造模，整体课题外包。
实验室一直都是用日常型质粒抽提试剂盒，转染细胞没问题。
我觉得只要是注意以下2点就可以了：
1，注意大肠杆菌(Escherichia coli)本身的污染，收集菌体沉淀时防止菌液散落，经常用75%的乙醇擦拭手套。
2，最后洗脱时最好使用无内毒素的水，我们是用注射用水的。
无论是小提还是大提我们都是用的日常型的，并没有刻意用转染级的，因为转染量大，去内毒素的操作太麻烦，损失太大。
转染分2种，一种是瞬时转染，即转染后让细胞表达目的蛋白后即提取蛋白，提一次蛋白，转染一次，这种方式一般不传代；
另一种转染为稳定转染，转染后加入一定选择压力进行筛选，没有转染的细胞不能存活，只留下转染的细胞，这种情况下可以筛选单个转染细胞，构建稳定表达某一特定蛋白或基因的细胞系。
